Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
The Food and Drug Administration approves once-daily Descovy for PrEP.
The authors of the largest study to date to analyze condoms’ failure rate are pushing the FDA to finally approve them for anal sex use.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The new indication is for prevention of sexually transmitted HIV, with the exception of transmission via receptive vaginal sex.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
Pretomanid triple therapy cuts the length of treatment from 18 months to six months.
Evidence supports new PrEP option for gay men and trans women, but there’s no consensus for other groups.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Previously, tests were approved only for use with genital or urine samples.
The spray requires no medical training.
Descovy and Truvada were both highly effective and generally safe options for HIV prevention in a recent clinical trial.
Check out this timeline of the HIV/AIDS in the United States from 1981 to the present.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Other countries already embrace this form of HIV prevention, also known as “on-demand,” “sex-driven” and “intermittent” PrEP.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.